Last reviewed · How we verify
NCT05009914
A New Way of Cardiac Denervation to Reduce the Incidence of AF After CABG.
NA trial testing cardiac denervation in Cardiac Denervation in 430 participants. Completed in 30 January 2024.
13 December 2023
Quick facts
| Lead sponsor | China National Center for Cardiovascular Diseases |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 430 |
| Start date | 15 August 2022 |
| Primary completion | 13 December 2023 |
| Estimated completion | 30 January 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- cardiac denervation
Conditions studied
- Cardiac Denervation — all drugs for Cardiac Denervation →
- Postoperative Atrial Fibrillation — all drugs for Postoperative Atrial Fibrillation →
Sponsor
China National Center for Cardiovascular Diseases — full company profile →
Who can join
18 and older, any sex, with Cardiac Denervation or Postoperative Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, random controlled trial(RCT) study. 430 patients undergoing coronary artery bypass grafting were enrolled. Our new way of cardiac denervation, defined as excision of Marshall ligament and Waterstone fat pad, was performed in 215 patients, and the other 215 patients were used as control subjects. All the patients need to equip with electronic monitor to record heart rhythms within 6 days after CABG. The investigators will compare the incidence of postoperative atrial fibrillation between two groups, and follow up 30 days after discharged.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Partial Cardiac Denervation to Prevent Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting: The pCAD-POAF Randomized Clinical Trial.
Yang Z, Tiemuerniyazi X, Xu F, Wang Y, et al · · 2025 · cited 7× · PMID 39550720 · DOI 10.1001/jamacardio.2024.4639
Verify or expand the search:
- PubMed search for NCT05009914
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other China National Center for Cardiovascular Diseases trials
Trials by the same sponsor.
- NCT07514988 — Sirolimus-Coated vs Paclitaxel-Coated DCBs in ACS Treatment · NA · not yet recruiting
- NCT07476456 — Skeletal Muscle Multi-omics Analysis and Risk Tailoring in Sudden Cardiac Death · not yet recruiting
- NCT07302659 — Aortic No-Touch vs Partial Aortic Clamping in Off-Pump CABG · NA · recruiting
- NCT07482683 — Predicting Post-Cardiac Surgery Acute Kidney Disease: A Machine Learning Approach · not yet recruiting
- NCT06787430 — Effects of Nicorandil on Microvascular Dysfunction in Patients With STEMI Undergoing Primary PCI · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05009914 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by China National Center for Cardiovascular Diseases
- Last refreshed: 13 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05009914.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing